Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 5;22(8):37.
doi: 10.1007/s11920-020-01164-1.

Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies

Jutta Stoffers-Winterling  1 , Ole Jakob Storebø  2   3 , Klaus Lieb  4
Affiliations
Review

Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies

Jutta Stoffers-Winterling et al. Curr Psychiatry Rep. .

Abstract

Purpose of the review: We aim to identify the most recent evidence of randomised controlled trials evaluating continued drug treatments in people with a diagnosis of BPD, review the most recent findings, highlight trends in terms of currently ongoing studies and comment on the overall body of evidence.

Recent findings: We identified seven new RCTs, plus newly available data for an older RCT. Only three of these RCTs have been published in full text, while we found study data posted at trial registry platforms for the others. The new findings do not support fluoxetine as a treatment option for suicide and self-harm prevention. A large effectiveness study did not detect beneficial effects of lamotrigine in routine care. The prevalent use of medications in BPD is still not reflected or supported by the current evidence. More research is needed regarding the most commonly used substances and substance classes, i.e. SSRIs, and quetiapine, but also with respect to people presenting with distinct comorbid conditions.

Keywords: Anticonvulsants; Antidepressants; Antipsychotics; Borderline personality disorder; Drug treatment; Review.

PubMed Disclaimer

Conflict of interest statement

Jutta Stoffers-Winterling, Ole Jakob Storebø and Klaus Lieb each declare no potential conflicts of interest.

Figures

Fig. 1
Fig. 1
Randomised and quasi-randomised controlled trials of drug treatments in people with personality disorders. Publications per year, 1980 to current; CENTRAL search 29 March 2020 (MeSH descriptor [borderline personality disorder] AND qualifier “drug therapy”)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. NHMRC. Clinical practice guideline for the management of borderline personality disorder [Internet]. Canberra: National Health and Medical Research Council; 2013 [cited 2016 Dec 1]. Available from: http://www.nhmrc.gov.au/guidelines/publications/mh25
    1. NICE National Institute for Health and Care Excellence. 2018 Surveillance of personality disorders (NICE guidelines CG77 and CG78). Surveillance report. Published 19 July 2018. Available from https://www.nice.org.uk/guidance/cg78/resources/2018-surveillance-of-per.... 2018. - PubMed
    1. Stoffers JM, Vollm BA, Rucker G, Timmer A, Huband N, Lieb K. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev [Internet]. 2012; Available from: ://WOS:000308220400007. - PMC - PubMed
    1. Storebø OJ, Stoffers-Winterling JM, Völlm BA, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2020;5(5):CD012955. 10.1002/14651858.CD012955.pub2. - PMC - PubMed
    1. Oud M, Arntz A, Hermens ML, Verhoef R, Kendall T. Specialized psychotherapies for adults with borderline personality disorder: a systematic review and meta-analysis. Aust N Z J Psychiatry. 2018;4867418791257. - PMC - PubMed